![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
ABSTRACT
Objective: The aim of the study was to evaluate the effect of gliclazide modified release (MR) treatment on adiponectin, interleukin 6 (IL-6), and tumor necrosis factor-α (TNF‐α) plasma concentrations in type 2 diabetic patients.
Research design and methods: 24 randomly selected type 2 diabetic patients, aged 61.2 ± 15.4 years, with poorly controlled glucose level (mean glycated hemoglobin [HbA1c] 7.6 ± 1.1%) despite treatment with diet and/or oral hypoglycemic agents, were included in the study. All of the patients, after a 2‐week run-in period, were given gliclazide MR for 12 weeks. At baseline, and after gliclazide MR treatment, HbA1c and plasma concentrations of IL‐6, TNF‐α, and adiponectin were measured.
Results: Gliclazide MR treatment produced significant reductions in fasting plasma glucose (from 7.6 ± 1.4 to 6.6 ± 1.2 mmol/L, p < 0.01), HbA1c (from 7.6 ± 1.1 to 6.9 ± 0.8%, p < 0.01), and plasma IL‐6 concentrations (from 2.5 ± 1.8 to 1.8 ± 1.2 pg/mL, p < 0.05). A significant increase in plasma adiponectin level was noted (from 6.4 ± 3.3 to 7.6 ± 4.4 µg/mL, p < 0.05). Plasma TNF‐α concentrations and homeostasis model assessment of insulin resistance (HOMA‐IR) decreased after treatment, but these changes did not reach statistical significance.
Conclusions: Gliclazide MR improves glycemic control and, in addition, has a positive influence on the plasma level of some inflammatory markers and adiponectin. Increased plasma adiponectin and decreased plasma IL‐6, and TNF‐α levels may explain, at least in part, the anti-atherogenic action of this drug reported elsewhere.